Feed RIGL
RI

Rigel Pharmaceuticals, Inc. RIGL NASDAQ · Healthcare · United States

$42.53 -0.91% -$0.39

Summary

88 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 107 USD is left as net profit.
  • Revenue grew by 35% a year over the last 3 years.
  • It earns 68 USD a year on every 100 USD of invested capital.
  • It holds more cash than debt: $46.6M against $7.79M.

What to watch

  • Its last loss-making year was 3 years ago.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Undervalued Price today $42.53

By our assumptions the business is worth more than its shares cost today.

P/E today 2.6
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 2.6 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 22% a year over 5 years. Over the last 3 years it grew by 35% a year.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Biotechnology) -10 USD

Out of every 100 USD of revenue, 107 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $67 is 58% above today's price. 53% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

The company reports no revenue by region.

Product brings in 79% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy